Work

Abstract A164: Cardiac effects in a first-in-human (FIH), pharmacokinetic (PK), pharmacodynamic (PD) phase I trial of JNJ-26481585, a second-generation oral hydroxamate histone deacetylase inhibitor (HDACi), in patients with refractory cancer.

Year: 2011

Type: conference-abstract

Source: Molecular Cancer Therapeutics

DOI: 10.1158/1535-7163.targ-11-a164

Authors: Rebecca S. Kristeleit, Richard D. Baird, Balaji Venugopal, Duncan K. Wilkins, Fiona MacCormick, Roberta Granata, Donna Crawford, Julie Charlton, John Camm, Peter Hellemans, Nele Fourneau, Yusri Elsayed, Richard Cowan, Udai Banerji, Ruth Plummer, Jeff Evans, Johann de Bono

Institutions: University College London, Royal Marsden Hospital, Beatson West of Scotland Cancer Centre, St George's, University of London, Janssen (Belgium), The Christie NHS Foundation Trust

Language: English

Topic: Histone Deacetylase Inhibitors Research

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2047902384

Cites:

Cited by:

Related to: 10